Project Juliett
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Opportunity
A drug discovery CRO established in 2005, with 54 employees and a single owner,
specializes in immuno-oncology, immune-modulation, and lung diseases through integrated
services in drug discovery, in vivo pharmacology, medicinal chemistry, bioanalytics, and
formulation, serving major clients like GSK, and generating $3M net revenue with $0.26M
EBITDA in 2022.
Company Profile
Established in 2005, this privately owned (single owner) drug discovery
service provider employs 54 multidisciplinary experts with fully integrated expertise across physiological, biological, pharmacological, and biochemical sciences. It offers comprehensive CRO
services including drug discovery, in vivo pharmacology, medicinal chemistry, bioanalytics, and formulation, with a global client base.
Therapeutic Focus
Specialized in high-value areas:
immuno-oncology, immunemodulation, and lung diseases, supported by additional small and large animal drug discovery services. The company has a proven track record serving major pharmaceutical clients, including big pharma such as GSK.
Financial Highlights
Stable service-based revenue model with net revenue of $3 million in 2022 and EBITDA of $0.26 million, reflecting a lean, profitable operation in a niche preclinical space.
Investment
The single owner is open to strategic options, presenting an attractive acquisition or partnership target: an established, experienced CRO with specialized focus in immuno-oncology and respiratory immunology, integrated capabilities, prestigious clientele, and strong potential for scaling through expanded partnerships or bolt-on growth in the growing immunotherapy and rare/respiratory disease markets.